Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Anxiety Disorders-Pipeline Review, H1 2015

Anxiety Disorders-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Anxiety Disorders-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Anxiety Disorders-Pipeline Review, H1 2015', provides an overview of the Anxiety Disorders's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Anxiety Disorders and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Anxiety Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Anxiety Disorders pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Anxiety Disorders Overview 10

Therapeutics Development 11

Pipeline Products for Anxiety Disorders-Overview 11

Pipeline Products for Anxiety Disorders-Comparative Analysis 12

Anxiety Disorders-Therapeutics under Development by Companies 13

Anxiety Disorders-Therapeutics under Investigation by Universities/Institutes 17

Anxiety Disorders-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Unknown Stage Products 22

Anxiety Disorders-Products under Development by Companies 23

Anxiety Disorders-Products under Investigation by Universities/Institutes 29

Anxiety Disorders-Companies Involved in Therapeutics Development 31

AbbVie Inc. 31

Ache Laboratorios Farmaceuticos S/A 32

Adamed Sp. z o.o. 33

Addex Therapeutics Ltd 34

Avineuro Pharmaceuticals, Inc. 35

Azevan Pharmaceuticals, Inc. 36

Beech Tree Labs, Inc. 37

Bionomics Limited 38

Boehringer Ingelheim GmbH 39

C4X Discovery Ltd 40

Catalyst Pharmaceutical Partners, Inc. 41

Concert Pharmaceuticals, Inc. 42

Edgemont Pharmaceuticals, LLC 43

Eisai Co., Ltd. 44

Eli Lilly and Company 45

F. Hoffmann-La Roche Ltd. 46

GW Pharmaceuticals plc 47

H. Lundbeck A/S 48

Heptares Therapeutics Ltd. 49

HolsboerMaschmeyer NeuroChemie GmbH 50

Humanetics Corporation 51

Intra-Cellular Therapies, Inc. 52

Johnson & Johnson 53

Marinus Pharmaceuticals, Inc. 54

Merz Pharmaceuticals GmbH 55

MI.TO. Technology S.r.L. 56

Nanotherapeutics, Inc. 57

Neuralstem, Inc. 58

Neurocrine Biosciences, Inc. 59

NeuroNascent, Inc. 60

Newron Pharmaceuticals S.p.A. 61

Novartis AG 62

Nuvo Research Inc. 63

Omeros Corporation 64

Otsuka Holdings Co., Ltd. 65

Pfizer Inc. 66

Polleo Pharma Limited 67

Rottapharm SpA 68

Sellas Inc. 69

SK Biopharmaceuticals Co., Ltd. 70

Suda Ltd 71

Sumitomo Dainippon Pharma Co., Ltd. 72

Tonix Pharmaceuticals Holding Corp. 73

Trevena, Inc. 74

Vanda Pharmaceuticals Inc. 75

Anxiety Disorders-Therapeutics Assessment 76

Assessment by Monotherapy Products 76

Assessment by Target 77

Assessment by Mechanism of Action 81

Assessment by Route of Administration 84

Assessment by Molecule Type 86

Drug Profiles 88

7-Keto-Drug Profile 88

ADN-2013-Drug Profile 89

ADX-71441-Drug Profile 90

ADX-71743-Drug Profile 91

ADX-88178-Drug Profile 92

alprazolam-Drug Profile 93

AVL-5189-Drug Profile 94

AVN-101-Drug Profile 95

AVN-397-Drug Profile 96

AVN-628-Drug Profile 97

AZ-01-Drug Profile 98

BCA-909-Drug Profile 99

bitopertin-Drug Profile 101

BNC-210-Drug Profile 103

brexpiprazole-Drug Profile 105

BTL-ng-Drug Profile 107

CPP-115-Drug Profile 108

CR-5542 Series-Drug Profile 110

CTP-354-Drug Profile 111

dipraglurant IR-Drug Profile 112

Drug for Post-Traumatic Stress Disorders-Drug Profile 113

Drugs to Activate HAT for CNS Disorders-Drug Profile 114

Drugs to Inhibit FAAH for CNS Disorders-Drug Profile 115

Drugs to Inhibit Histone Deacetylase for CNS Disorders-Drug Profile 116

Drugs to Modulate NPSR for Anxiety Disorder-Drug Profile 117

Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders-Drug Profile 118

E-2508-Drug Profile 119

EDG-008-Drug Profile 120

fluvoxamine maleate-Drug Profile 121

ganaxolone-Drug Profile 122

iloperidone-Drug Profile 124

ITI-007-Drug Profile 126

itriglumide-Drug Profile 128

JNJ-31020028-Drug Profile 129

JNJ-42165279-Drug Profile 130

lorazepam ER-Drug Profile 131

LSN-2535717-Drug Profile 132

LY-2607540-Drug Profile 133

mavoglurant-Drug Profile 134

methoxycoronaridine-Drug Profile 136

midazolam hydrochloride-Drug Profile 137

MRZ-8676-Drug Profile 138

nabiximols-Drug Profile 139

NB-51R1-Drug Profile 142

NNI-351-Drug Profile 143

NSI-189-Drug Profile 144

NTC-942-Drug Profile 145

NW-3509-Drug Profile 146

OMS-527-Drug Profile 147

Peptide to Activate NPSR for Sleep Disorders and Anxiety Disorders-Drug Profile 148

Peptide to Antagonize PACAP Receptor for CNS and Overactive Bladder-Drug Profile 149

PF-06372865-Drug Profile 150

PT-00114-Drug Profile 151

PT-00121-Drug Profile 152

PT-00211-Drug Profile 153

PT-00411-Drug Profile 154

Ro-646198-Drug Profile 155

Rycal-Drug Profile 156

S-107-Drug Profile 157

SCT-66-Drug Profile 158

Small Molecule to Agonize mGluR2 for Anxiety Disorders-Drug Profile 159

Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders-Drug Profile 160

Small Molecule to Antagonize GPR31 for Anxiety Disorders-Drug Profile 161

Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders-Drug Profile 162

Small Molecule to Modulate Glutamate Receptor for Anxiety Disorders-Drug Profile 163

Small Molecule to Target GPR151 for CNS Diseases-Drug Profile 165

Small Molecule to Target GPR83 for CNS and Immunological Disorders-Drug Profile 166

Small Molecules for BED and PTSD-Drug Profile 167

Small Molecules for Depression and Anxiety-Drug Profile 168

Small Molecules for Post-Traumatic Stress Disorder-Drug Profile 169

Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders-Drug Profile 170

Small Molecules to Activate Sigma Receptor for Panic and Schizoaffective Disorders-Drug Profile 171

Small Molecules to Activate Translocator Protein for Anxiety-Drug Profile 172

Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders-Drug Profile 173

Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder-Drug Profile 174

Small Molecules to Agonize Mineralocorticoid Receptor for Depression and Anxiety-Drug Profile 175

Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders-Drug Profile 176

Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders-Drug Profile 177

Small Molecules to Antagonize TLR-4 for CNS Disorders-Drug Profile 178

Small Molecules to Inhibit DAT and SERT for CNS Disorders-Drug Profile 179

Small Molecules to Inhibit mGluR7 For Central Nervous System Disorders-Drug Profile 180

Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy-Drug Profile 181

Small Molecules to Target Oxytocin for Autism and Anxiety Disorders-Drug Profile 182

SRX-246-Drug Profile 183

SRX-251-Drug Profile 185

Synthetic Peptide for Anxiety Disorders-Drug Profile 187

tedatioxetine-Drug Profile 188

TNX-102-Drug Profile 190

TPI-136117-Drug Profile 192

TRV-250-Drug Profile 193

UCM-765-Drug Profile 194

Vaccine for Post-Traumatic Stress Disorder and Depression-Drug Profile 195

VAD-1-Drug Profile 196

VAD-2-Drug Profile 197

verucerfont-Drug Profile 198

vigabatrin-Drug Profile 200

vortioxetine hydrobromide-Drug Profile 203

YKP-3089-Drug Profile 206

ZL-006-Drug Profile 208

zolpidem tartrate-Drug Profile 209

Anxiety Disorders-Recent Pipeline Updates 210

Anxiety Disorders-Dormant Projects 246

Anxiety Disorders-Discontinued Products 258

Anxiety Disorders-Product Development Milestones 263

Featured News & Press Releases 263

Appendix 270

Methodology 270

Coverage 270

Secondary Research 270

Primary Research 270

Expert Panel Validation 270

Contact Us 270

Disclaimer 271

List of Tables

Number of Products under Development for Anxiety Disorders, H1 2015 18

Number of Products under Development for Anxiety Disorders-Comparative Analysis, H1 2015 19

Number of Products under Development by Companies, H1 2015 20

Number of Products under Development by Companies, H1 2015 (Contd..1) 21

Number of Products under Development by Companies, H1 2015 (Contd..2) 22

Number of Products under Development by Companies, H1 2015 (Contd..3) 23

Number of Products under Investigation by Universities/Institutes, H1 2015 25

Comparative Analysis by Late Stage Development, H1 2015 26

Comparative Analysis by Clinical Stage Development, H1 2015 27

Comparative Analysis by Early Stage Development, H1 2015 28

Comparative Analysis by Unknown Stage Development, H1 2015 29

Products under Development by Companies, H1 2015 30

Products under Development by Companies, H1 2015 (Contd..1) 31

Products under Development by Companies, H1 2015 (Contd..2) 32

Products under Development by Companies, H1 2015 (Contd..3) 33

Products under Development by Companies, H1 2015 (Contd..4) 34

Products under Development by Companies, H1 2015 (Contd..5) 35

Products under Investigation by Universities/Institutes, H1 2015 36

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 37

Anxiety Disorders-Pipeline by AbbVie Inc., H1 2015 38

Anxiety Disorders-Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2015 39

Anxiety Disorders-Pipeline by Adamed Sp. z o.o., H1 2015 40

Anxiety Disorders-Pipeline by Addex Therapeutics Ltd, H1 2015 41

Anxiety Disorders-Pipeline by Avineuro Pharmaceuticals, Inc., H1 2015 42

Anxiety Disorders-Pipeline by Azevan Pharmaceuticals, Inc., H1 2015 43

Anxiety Disorders-Pipeline by Beech Tree Labs, Inc., H1 2015 44

Anxiety Disorders-Pipeline by Bionomics Limited, H1 2015 45

Anxiety Disorders-Pipeline by Boehringer Ingelheim GmbH, H1 2015 46

Anxiety Disorders-Pipeline by C4X Discovery Ltd, H1 2015 47

Anxiety Disorders-Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2015 48

Anxiety Disorders-Pipeline by Concert Pharmaceuticals, Inc., H1 2015 49

Anxiety Disorders-Pipeline by Edgemont Pharmaceuticals, LLC, H1 2015 50

Anxiety Disorders-Pipeline by Eisai Co., Ltd., H1 2015 51

Anxiety Disorders-Pipeline by Eli Lilly and Company, H1 2015 52

Anxiety Disorders-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 53

Anxiety Disorders-Pipeline by GW Pharmaceuticals plc, H1 2015 54

Anxiety Disorders-Pipeline by H. Lundbeck A/S, H1 2015 55

Anxiety Disorders-Pipeline by Heptares Therapeutics Ltd., H1 2015 56

Anxiety Disorders-Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H1 2015 57

Anxiety Disorders-Pipeline by Humanetics Corporation, H1 2015 58

Anxiety Disorders-Pipeline by Intra-Cellular Therapies, Inc., H1 2015 59

Anxiety Disorders-Pipeline by Johnson & Johnson, H1 2015 60

Anxiety Disorders-Pipeline by Marinus Pharmaceuticals, Inc., H1 2015 61

Anxiety Disorders-Pipeline by Merz Pharmaceuticals GmbH, H1 2015 62

Anxiety Disorders-Pipeline by MI.TO. Technology S.r.L., H1 2015 63

Anxiety Disorders-Pipeline by Nanotherapeutics, Inc., H1 2015 64

Anxiety Disorders-Pipeline by Neuralstem, Inc., H1 2015 65

Anxiety Disorders-Pipeline by Neurocrine Biosciences, Inc., H1 2015 66

Anxiety Disorders-Pipeline by NeuroNascent, Inc., H1 2015 67

Anxiety Disorders-Pipeline by Newron Pharmaceuticals S.p.A., H1 2015 68

Anxiety Disorders-Pipeline by Novartis AG, H1 2015 69

Anxiety Disorders-Pipeline by Nuvo Research Inc., H1 2015 70

Anxiety Disorders-Pipeline by Omeros Corporation, H1 2015 71

Anxiety Disorders-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 72

Anxiety Disorders-Pipeline by Pfizer Inc., H1 2015 73

Anxiety Disorders-Pipeline by Polleo Pharma Limited, H1 2015 74

Anxiety Disorders-Pipeline by Rottapharm SpA, H1 2015 75

Anxiety Disorders-Pipeline by Sellas Inc., H1 2015 76

Anxiety Disorders-Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 77

Anxiety Disorders-Pipeline by Suda Ltd, H1 2015 78

Anxiety Disorders-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 79

Anxiety Disorders-Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2015 80

Anxiety Disorders-Pipeline by Trevena, Inc., H1 2015 81

Anxiety Disorders-Pipeline by Vanda Pharmaceuticals Inc., H1 2015 82

Assessment by Monotherapy Products, H1 2015 83

Number of Products by Stage and Target, H1 2015 86

Number of Products by Stage and Mechanism of Action, H1 2015 89

Number of Products by Stage and Route of Administration, H1 2015 92

Number of Products by Stage and Molecule Type, H1 2015 94

Anxiety Disorders Therapeutics-Recent Pipeline Updates, H1 2015 217

Anxiety Disorders-Dormant Projects, H1 2015 253

Anxiety Disorders-Dormant Projects (Contd..1), H1 2015 254

Anxiety Disorders-Dormant Projects (Contd..2), H1 2015 255

Anxiety Disorders-Dormant Projects (Contd..3), H1 2015 256

Anxiety Disorders-Dormant Projects (Contd..4), H1 2015 257

Anxiety Disorders-Dormant Projects (Contd..5), H1 2015 258

Anxiety Disorders-Dormant Projects (Contd..6), H1 2015 259

Anxiety Disorders-Dormant Projects (Contd..7), H1 2015 260

Anxiety Disorders-Dormant Projects (Contd..8), H1 2015 261

Anxiety Disorders-Dormant Projects (Contd..9), H1 2015 262

Anxiety Disorders-Dormant Projects (Contd..10), H1 2015 263

Anxiety Disorders-Dormant Projects (Contd..11), H1 2015 264

Anxiety Disorders-Discontinued Products, H1 2015 265

Anxiety Disorders-Discontinued Products (Contd..1), H1 2015 266

Anxiety Disorders-Discontinued Products (Contd..2), H1 2015 267

Anxiety Disorders-Discontinued Products (Contd..3), H1 2015 268

Anxiety Disorders-Discontinued Products (Contd..4), H1 2015 269

List of Figures

Number of Products under Development for Anxiety Disorders, H1 2015 18

Number of Products under Development for Anxiety Disorders-Comparative Analysis, H1 2015 19

Number of Products under Development by Companies, H1 2015 20

Number of Products under Investigation by Universities/Institutes, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 27

Comparative Analysis by Early Stage Products, H1 2015 28

Assessment by Monotherapy Products, H1 2015 83

Number of Products by Top 10 Targets, H1 2015 84

Number of Products by Stage and Top 10 Targets, H1 2015 85

Number of Products by Top 10 Mechanism of Actions, H1 2015 88

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 88

Number of Products by Top 10 Routes of Administration, H1 2015 91

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 92

Number of Products by Top 10 Molecule Types, H1 2015 93

Number of Products by Stage and Top 10 Molecule Types, H1 2015 94

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Ache Laboratorios Farmaceuticos S/A

Adamed Sp. z o.o.

Addex Therapeutics Ltd

Avineuro Pharmaceuticals, Inc.

Azevan Pharmaceuticals, Inc.

Beech Tree Labs, Inc.

Bionomics Limited

Boehringer Ingelheim GmbH

C4X Discovery Ltd

Catalyst Pharmaceutical Partners, Inc.

Concert Pharmaceuticals, Inc.

Edgemont Pharmaceuticals, LLC

Eisai Co., Ltd.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

GW Pharmaceuticals plc

H. Lundbeck A/S

Heptares Therapeutics Ltd.

HolsboerMaschmeyer NeuroChemie GmbH

Humanetics Corporation

Intra-Cellular Therapies, Inc.

Johnson & Johnson

Marinus Pharmaceuticals, Inc.

Merz Pharmaceuticals GmbH

MI.TO. Technology S.r.L.

Nanotherapeutics, Inc.

Neuralstem, Inc.

Neurocrine Biosciences, Inc.

NeuroNascent, Inc.

Newron Pharmaceuticals S.p.A.

Novartis AG

Nuvo Research Inc.

Omeros Corporation

Otsuka Holdings Co., Ltd.

Pfizer Inc.

Polleo Pharma Limited

Rottapharm SpA

Sellas Inc.

SK Biopharmaceuticals Co., Ltd.

Suda Ltd

Sumitomo Dainippon Pharma Co., Ltd.

Tonix Pharmaceuticals Holding Corp.

Trevena, Inc.

Vanda Pharmaceuticals Inc.

Anxiety Disorders Therapeutic Products under Development, Key Players in Anxiety Disorders Therapeutics, Anxiety Disorders Pipeline Overview, Anxiety Disorders Pipeline, Anxiety Disorders Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com